First prospective trial of a glucagon-like peptide (GLP-2) analog in SR GI aGVHD Results up to Day 91 show that apraglutide in SR GI aGVHD was well-tolerated with an acceptable safety profile, the study’s primary objective Exploratory secondary efficacy data showed lower GI tract responses maintained through Day 91 in SR GI aGVHD patients treated with apraglutide and standard of care BOSTON / Mar 28, 2024 / Business Wire /... Read More

Apraglutide met the primary endpoint of relative change from baseline in actual weekly parenteral support (PS) volume at week 24, driven by both stoma and colon-in-continuity populations Apraglutide also showed a clinically meaningful improvement at week 24, with patients achieving at least one day off PS per week Apraglutide was generally well-tolerated, and the safety profile was consistent with previously-reported studies... Read More

Apraglutide nutritional data from STARS Nutrition Phase 2 study in adult patients who have short bowel syndrome with intestinal failure and colon-in-continuity will be highlighted in an oral presentation Additional data on apraglutide from previously completed Phase 1 and Phase 2 studies will also be highlighted in poster presentations BOSTON / Feb 23, 2024 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a... Read More

LINZESS ® (Iinaclotide) 2023 U.S. net sales of $1.1 billion, an increase of 7% year-over-year, driven by EUTRx prescription demand growth of 10% year-over-year 2023 Ironwood revenue of $443 million, driven primarily by $430 million in U.S. LINZESS collaboration revenue Continues to expect topline results from the STARS Phase III study of apraglutide in patients with short bowel syndrome with intestinal failure (SBS-IF) in... Read More

BOSTON / Feb 01, 2024 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 15, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (647) 495-7514 (international) using conference ID number and event... Read More

Newly published data highlights additional efficacy endpoints from trial Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years with functional constipation BOSTON / Jan 08, 2024 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that new data from the Phase III study that evaluated linaclotide in children... Read More

Expects high-single digit percentage LINZESS® EUTRx prescription demand growth in 2024 Expects 2024 adjusted EBITDA of greater than $150 million BOSTON / Jan 08, 2024 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced financial guidance for full year 2024. The results were announced in advance of the Company’s presentation at the 42 nd Annual J.P. Morgan... Read More

BOSTON / Jan 03, 2024 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 11:15 a.m. Pacific Time / 2:15 p.m. Eastern Time at The Westin St. Francis in San Francisco, CA. A live audio webcast of Ironwood’s presentation will be accessible... Read More

BOSTON / Dec 12, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, today announced the successful completion of the squeeze-out merger under Swiss law (the “Squeeze-Out Merger”) pursuant to which VectivBio Holding AG (“VectivBio”) has been merged with and into Ironwood Pharmaceuticals GmbH (“Merger Sub”), a wholly-owned subsidiary of Ironwood organized under... Read More

BOSTON / Nov 21, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:00 a.m. ET at the Lotte New York Palace. A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com . To access the webcast,... Read More

LINZESS ® (Iinaclotide) EUTRx prescription demand growth increased 8% year-over-year; LINZESS U.S. net sales of $279 million, an increase of 7% year-over-year Reported positive final data from STARS Nutrition, a Phase II study of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) and colon-in-continuity (CIC) Expects topline data for the Phase II study of CNP-104 in primary biliary cholangitis (PBC) in the... Read More

BOSTON / Oct 26, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 9, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To... Read More

Data reinforce the impact of linaclotide on symptoms of IBS-C and CIC Additional studies highlight the burden of these disorders on patients BOSTON / Oct 23, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented new data from four scientific abstracts during the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting and Postgraduate Course.... Read More

Data show approximately 50% reduction of parenteral support (PS) volume 100% of patients were clinical responders 78% of patients achieved one or more days off PS Results support apraglutide as a potentially best-in-class glucagon-like peptide-2 (GLP-2) analog for the spectrum of patients with SBS-IF BOSTON / Oct 16, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company,... Read More

Data demonstrates that linaclotide reduces the need for rescue medications in this patient population Additional presentations further characterize the efficacy and safety profiles of linaclotide as the only FDA-approved prescription therapy for this patient population Functional constipation affects an estimated 6 million children and adolescents ages 6-17 years-old in the U.S. 1 ­ BOSTON / Oct 05, 2023 / Business Wire /... Read More

LINZESS (Iinaclotide) EUTRx prescription demand growth increased 9% year-over-year; LINZESS U.S. net sales of $270 million, an increase of 9% year-over-year Expands clinical utility of LINZESS with FDA approval for pediatric patients ages 6-17 years-old suffering from functional constipation (FC) Strengthens GI development portfolio with acquisition of VectivBio Holding AG and its lead investigational asset, apraglutide, for... Read More

BOSTON / Jul 25, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, August 8, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To... Read More

BOSTON & BASEL, Switzerland / Jun 29, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the... Read More

BOSTON & BASEL, Switzerland / Jun 16, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that the waiting period under the Hart-Scott-Rodino Antitrust... Read More

LINZESS is the first and only FDA-approved prescription therapy for functional constipation in this patient population Approval brings a much-needed option to an estimated 6 million 6-17-year-olds in the U.S. 1 affected by this chronic, prevalent condition BOSTON / Jun 12, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug... Read More

Transaction Advances Ironwood’s Vision of Becoming the Leading GI Healthcare Company Adds apraglutide, Next Generation, Synthetic GLP-2 Analog in Phase 3 for Short Bowel Syndrome with Intestinal Failure (SBS-IF); Potential to become Best-in-Class for SBS-IF Orphan Drug Designation Received for Treatment of Adult Patients with SBS-IF; Topline Results of Phase 3 Trial Expected by the End of 2023 Ironwood to Commence All-Cash... Read More

BOSTON / May 09, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 1:30 p.m. ET at the New York Hilton Midtown. A live audio webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com . To... Read More

Additional data presentations further characterize the efficacy and safety profiles of linaclotide in this patient population Functional constipation affects an estimated 6 million 6-17 year-olds in the U.S. 1 ­; there are currently no FDA-approved prescription therapies BOSTON / May 08, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented findings during the 2023... Read More

LINZESS (Iinaclotide) EUTRx prescription demand growth increased 10% year-over-year; LINZESS U.S. net sales of $250 million, an increase of 8% year-over-year GAAP net income of $46 million and adjusted EBITDA of $60 million; ended Q1 2023 with $740 million in cash and cash equivalents BOSTON / May 04, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its... Read More

Pivotal Phase III data will be spotlighted via an oral presentation Additional efficacy and safety data will be featured across four posters BOSTON / Apr 24, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings during the 2023 Digestive Disease Week® (DDW) from studies on the potential of linaclotide for children and... Read More

BOSTON / Apr 20, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 4, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To... Read More

BOSTON / Feb 27, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will participate in the following investor conferences: Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:10 a.m. ET at the Boston Marriott Copley Place Barclays Global Healthcare Conference on Tuesday, March 14, 2023 at 8:00 a.m. ET at the Loews Miami... Read More

BOSTON / Feb 13, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for LINZESS ® (linaclotide) for the treatment of children and adolescents ages 6-17 years-old with functional constipation (FC). The FDA has assigned the application a... Read More

BOSTON / Feb 02, 2023 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 16, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event... Read More

sNDA submitted to U.S. FDA in December 2022 seeking approval of a new indication of LINZESS® (linaclotide) for functional constipation in children and adolescents 6 to 17 years of age Expects high single-digit LINZESS® EUTRx prescription demand growth in 2023 Expects 2023 adjusted EBITDA of greater than $250 million Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided updated... Read More

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time at The Westin St. Francis in San Francisco, CA. A live audio webcast of Ironwood’s presentation will be accessible through the Investors section of the... Read More